- Home
- NUVL vs KD Comparison
NUVL vs KD Comparison
Compare NUVL & KD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- KD
- Stock Information
- Founded
- NUVL 2017
- KD 2020
- Country
- NUVL United States
- KD United States
- Employees
- NUVL N/A
- KD N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- KD EDP Services
- Sector
- NUVL Health Care
- KD Technology
- Exchange
- NUVL Nasdaq
- KD Nasdaq
- Market Cap
- NUVL 7.1B
- KD 6.1B
- IPO Year
- NUVL 2021
- KD N/A
- Fundamental
- Price
- NUVL $109.19
- KD $23.70
- Analyst Decision
- NUVL Strong Buy
- KD Buy
- Analyst Count
- NUVL 13
- KD 5
- Target Price
- NUVL $133.85
- KD $41.60
- AVG Volume (30 Days)
- NUVL 734.4K
- KD 2.9M
- Earning Date
- NUVL 10-30-2025
- KD 11-04-2025
- Dividend Yield
- NUVL N/A
- KD N/A
- EPS Growth
- NUVL N/A
- KD N/A
- EPS
- NUVL N/A
- KD 1.68
- Revenue
- NUVL N/A
- KD $15,008,000,000.00
- Revenue This Year
- NUVL N/A
- KD $6.80
- Revenue Next Year
- NUVL N/A
- KD $2.41
- P/E Ratio
- NUVL N/A
- KD $14.12
- Revenue Growth
- NUVL N/A
- KD N/A
- 52 Week Low
- NUVL $55.54
- KD $23.28
- 52 Week High
- NUVL $112.88
- KD $44.20
- Technical
- Relative Strength Index (RSI)
- NUVL 66.08
- KD 24.64
- Support Level
- NUVL $93.05
- KD $23.28
- Resistance Level
- NUVL $112.53
- KD $26.45
- Average True Range (ATR)
- NUVL 5.84
- KD 1.17
- MACD
- NUVL 1.06
- KD -0.26
- Stochastic Oscillator
- NUVL 84.34
- KD 6.24
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About KD Kyndryl Holdings Inc.
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.